Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback

What: Anaptys Bio is spinning off First Tracks Biotherapeutics, a subsidiary focused on rare genetic diseases.
Why: The spin-off aims to increase focus on core business and allow First Tracks to pursue its own growth strategies.
Signal: The move indicates a strategic shift in Anaptys Bio's priorities, potentially signaling a change in market direction.
Target: The company is targeting a more streamlined and focused approach to its business operations.
Risk: The spin-off may pose risks to Anaptys Bio's financial stability, particularly if First Tracks underperforms.